|
Ranbaxy acquires generic product portfolio from Efarmes
EPP News Bureau - Mumbai
Ranbaxy Laboratories Limited has acquired a generic product
portfolio accounting for eighteen products belonging to the Spanish pharmaceutical
company Efarmes, SA for sale in the Spanish market. The products belong to the
cardio vascular system (CVS), central nervous system (CNS) and pain management
segments.
|
The acquisition fortifies Ranbaxy’s presence in
Spain while augmenting its existing product portfolio
|
The agreement has been entered between Barcelona based, Laboratorios
Ranbaxy SL, the wholly owned subsidiary of Ranbaxy and Efarmes of Spain, said
a release.
Commenting on the development, Peter Burema, Regional Director Europe, CIS &
Africa of Ranbaxy said, ‘‘We are happy to join hands with Efarmes.
The acquisition fortifies our presence in Spain while augmenting our existing
product portfolio. With this strategic development, we will be able to provide
a wide range of quality generics to meet the growing needs of patients in this
part of the world.’’
With a prescription medicine market, valued at around US $10 billion and growing
at approximately 10 per cent per annum, Spain today ranks ninth in the world
for prescription pharmaceuticals and fifth in the EU.
The current generic market is valued at US $700 mn and is estimated to be growing
at 30 per cent per annum.
|
